Core Viewpoint - Aspira Women's Health Inc. is set to report its financial results for Q1 2024 on May 15, 2024, and will host a conference call to discuss these results and provide a corporate update [1]. Company Overview - Aspira Women's Health Inc. focuses on the development of noninvasive, AI-powered diagnostic tests for gynecologic diseases, particularly ovarian cancer [3]. - The company offers OvaWatch® and Ova1Plus® as part of its OvaSuite®, which is the only comprehensive portfolio of blood tests for detecting ovarian cancer in over 1.2 million American women diagnosed with an adnexal mass annually [3]. - OvaWatch has a negative predictive value of 99%, helping to assess ovarian cancer risk in cases where initial assessments are indeterminate or benign [3]. Product Development - Aspira is expanding its ovarian cancer portfolio and developing noninvasive diagnostics for endometriosis, which affects millions of women globally [4]. - The OvaMDxSM risk assessment aims to enhance the sensitivity and specificity of current tests by combining microRNA and protein biomarkers with patient data [4]. - EndoCheckSM is the first noninvasive test designed to identify endometriomas, while EndoMDxSM will also combine microRNA and protein biomarkers with patient data to identify all forms of endometriosis [4].
Aspira Women's Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15